Introduction Hyperosmolar therapy with mannitol or hypertonic saline (HTS) is the primary medical management strategy for elevated intracranial pressure (ICP). La solución salina isoncótica-hipertónica [NaCl 7,2%/ HES (/0,5) 6%] y manitol (20%), en dosis única con carga osmolar equivalente, fueron efectivos y . isoncótica hipertônica versus manitol (20%) durante neuroanestesia eletiva manitol versus solución isoncótica hipertónica (SIH), durante la neurocirugía.
|Published (Last):||20 December 2016|
|PDF File Size:||14.87 Mb|
|ePub File Size:||11.11 Mb|
|Price:||Free* [*Free Regsitration Required]|
Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance.
The use of mannitol and hypertonic saline solution in neurocritical patients varies considerably among centres and there is no consensus regarding which of the two is the agent of choice.
Therefore, in the brain, remains in the vascular fluid compartment and thus removes the intracellular space and intersticial. Aggravation of vasogenic cerebral edema by multiple-dose mannitol.
Mannitol versus hypertonic saline solution in neuroanaesthesia
It is an effective alternative to mannitol in intracranial surgery. Evidence supporting mantiol of the literature regarding mannitol is reported from the trauma population and is subsequently general ized to other cohorts. Inthey evaluated these potential complications with HTS and 0.
Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: Intraocular and intracranial pressure: They measured haemodynamic variables, fluid balance, blood gases, lactate and osmolality blood, CSF and urine. Am J Med Sci. Th is review identifi es seven additional studies supporting the effi cacy of mannitol, of which one study is class II and the remainder are class III.
Cerebral hemodynamic effects of 7. Both mannitol and HTS have proven to be effective at controlling ICP, through different mechanisms; osmotic dehydration of the cerebral interstitium; reduction of blood viscosity; increased red blood cell deformation; and improved microcirculation. We conducted this research in order to assess the benefits and side effects of osmotherapy and to identify the current trends in the management of IH and cerebral oedema.
Solucion Hipertonica vs Manitol en HEC
It is important to note that in patients with impaired renal function the total dose of mannitol that may cause ARF may be lower than that in patients with normal renal function. Safety of hypertonic hyperoncotic solutions-a survey from Austria.
While the effi cacy of both agents for ICP reduction has been demonstrated , the relatively small amount of actual class I evidence supporting mannitol pales in comparison with that of HTS. This growing popularity has come about in response to the complications associated with the use of mannitol, in particular ARF and ICP rebound, because although it is not clear whether it worsens the neurological outcome, hhipertonica is still an important concern.
During the s, beneficial effects using small HHS boluses were shown in resuscitation in trauma, both in humans as well as in animal studies. The effect of high-dose mannitol on serum and urine solucioj and osmolality in neurosurgical patients. It has been very difficult to assess the efficacy of hypertonic saline solution or compare it with other protocols used for mannitol due to the wide variety of concentrations available and the number of protocols employed.
He determined that No ICP rebound effect was observed in any of the trials during their respective study periods. J Neurosurg The mechanism proposed to explain this phenomenon is the loss across the BBB which creates a decreasing gradient that may eventually be reverted.
In contrast, those who preferred mannitol mentioned longer experience with the drug and ease of use because no central venous access is required. Marko Critical Care Fluid replacement is required to avoid hypovolemia and subsequent secondary ischaemia or ICP elevation from reflex vasodilation of cerebral arterioles.
Mannitol causes compensatory cerebral vasoconstriction and vasodilation sokucion response to blood viscosity changes.
En el presente articulo mostramos la evidencia actual que soporta a la SSH y al manitol y cual se considera la mejor opcion como terapia medica en el tratamiento de la HIC. There is no Class I evidence showing superiority of one agent over another in the management of cerebral oedema and IH from different aetiologies in critically ill patients.
Although varying in methodology, nine of the 12 studies including fi ve class I studies demonstrate that HTS provides superior control of ICP over mannitol .
There are no pharmacokinetic data on HTS, but Lazaridis suggests that the onset of the effects is similar to that of mannitol. All of the measurements were recorded at the beginning of the study, before treatment, and 15, 30, 60, and min after treatment.